Abstract. The serum level of ß1,4-galactosyltransferase (ß1,4-GalT) is increased in both malignancy and benign diseases. Galactosyltransferase associated with tumor (GAT) is one of the soluble forms of ß1,4-GalT, and is a marker of ovarian cancer with a high specificity. GAT and normal soluble ß1,4-GalT are both derived from the same membrane-bound form of the enzyme. This study investigated the mechanism of GAT elevation in patients with ovarian cancer. The serum levels of GAT and normal ß1,4-GalT were measured using specific monoclonal antibodies. In addition, nude mice bearing human ovarian cancer were used to assess the kinetics of tumor-derived enzymes. GAT and normal ß1,4-GalT were both detected in ovarian cancer patients, but only GAT reflected the tumor status. In tumor-bearing nude mice, both soluble forms of ß1,4-GalT were released from tumor cells, but the half-life of GAT was far shorter than that of normal ß1,4-GalT. Addition of serum from healthy women to colostrum (which has a high GAT content) reduced the GAT level, while adding patient serum caused a significantly smaller reduction of GAT. Addition of the serum from mouse which includes no human ß1,4-GalT to colostrum also reduced the GAT level with no significant change of total soluble ß1,4-GalT. These findings indicate that human serum contains certain factors that decrease the GAT level, but these factors are inhibited in ovarian cancer patients so that a high GAT level persists. It seems that the decrease of GAT occurs as a result of conversion into normal ß1,4-GalT.
Introduction
Measurement of serum tumor markers and diagnostic imaging methods such as ultrasound are routinely combined to detect ovarian cancer. Among the various tumor markers, CA125 is used most frequently (1,2) because of its high positive rate (70-97%) in ovarian cancer (1) (2) (3) (4) (5) . However, from 20 to 50% of patients with benign ovarian tumors, including endometrial cysts that are far more common than ovarian cancer, are also positive for CA125 (3, (5) (6) (7) (8) . Therefore, the serum CA125 level cannot be used to differentiate malignant and benign ovarian tumors.
Unlike CA125, galactosyltransferase associated with tumor (GAT) shows a high specificity, since 50% of patients with ovarian cancer are positive for GAT, while the false-positive rate is only 4.5% among patients with benign ovarian tumors or endometrial cysts. Accordingly, GAT has been applied clinically as a marker for distinguishing ovarian cancer from other ovarian diseases, including benign tumors and endometrial cysts (5, 9) .
GAT is a soluble form of ß1,4-galactosyltransferase (ß1,4-GalT), which is derived from the membrane-bound enzyme (10) . ß1,4-GalT is one of the glycosyltransferases and is normally localized in the trans Golgi lamellae of mammalian cells. It transfers a galactose residue from UDP-galactose to the terminal N-acetylglucosamine of carbohydrate structures to form galactose-N-acetylglucosamine in a ß1,4-linkage (11) . The membrane-bound form of ß1,4-GalT is cleaved at the stem region to become the soluble form that is released into body fluids, such as serum, pleural fluid, ascites, and breast milk. The soluble form can be classified as either GAT or normal GalT, which is always detected in serum from normal persons. These two soluble forms can be separated by non-denaturing polyacrylamide gel electrophoresis, since GAT produces a slower migrating broad band than normal GalT and aggregates to form homopolymers after treatment with 2-mercaptoethanol (12) . These two types of soluble ß1,4-GalT are reported to be derived from the same membrane-bound form encoded by a common cDNA, although GAT is a slightly longer peptide (13) .
It seems possible that some factor specifically causes GAT to increase in patients with ovarian cancer and this factor is suggested to act post-translationally. In order to clarify the mechanism of serum GAT elevation, we first evaluated the changes of GAT and normal GalT after resection of ovarian cancer. Then we used an antibody specific to human ß1,4-GalT and mice bearing human ovarian cancer to assess the serum levels of soluble ß1,4-GalT exclusively derived from the tumor without the influence of soluble enzyme released from other organs. Finally, we examined the effect of serum from healthy persons or cancer patients and that of serum from mouse on the stability of GAT.
Materials and methods
Collection of human serum samples. Eight patients with epithelial ovarian cancer, who underwent surgery in the Department of Obstetrics and Gynecology of Keio University Hospital, were enrolled. Serum samples were collected preoperatively and 1 month after tumor resection. The mean age of the patients was 54.2 years. The ovarian tumor was histologically classified as serous adenocarcinoma (n=2), endometrioid adenocarcinoma (n=2), clear cell adenocarcinoma (n=2), or mucinous adenocarcinoma (n=2). Five healthy female volunteers were enrolled as controls and their serum samples were also collected. Informed consent was obtained from all the subjects before blood collection.
Cancer cell lines. The cancer cell lines used in the present study included RMG-I derived from human ovarian clear cell adenocarcinoma (14) , RTSG from poorly differentiated ovarian adenocarcinoma (15) , SKG-IIIa and SKG-IIIb from cervical squamous cell carcinoma (16, 17) , and SNG-II from endometrial adenocarcinoma (18) . Each cell line was cultured in F-12 medium (Gibco BRL, Rockville, USA) supplemented with 10% fetal calf serum (FCS: Mitsubishi Chemical Corp., Tokyo) at 37˚C in an atmosphere of 5% CO 2 . The medium was changed on days 2 and 5 of culture. Supernatant and cells were harvested close to confluence.
Experimental animals. Five-week-old female nu/nu mice and 5-week-old female Balb-c mice were used. The animals were handled in accordance with the guidelines for animal experimentation established by the School of Medicine at Keio University.
Serum samples from patients with ovarian cancer may contain soluble ß1,4-GalT derived from tumor tissue as well as that derived from normal tissues, but distinguishing their origin is considered to be impossible. In mice bearing the human ovarian cancer cell line RMG-I, however, soluble ß1,4-GalT derived from tumor cells could be detected without the influence of enzyme derived from normal tissues by using a specific antibody for soluble human ß1,4-GalT. Mice bearing RMG-I tumors were prepared as follows: RMG-I cells were suspended at 10 8 /ml and 0.5 ml of this suspension was subcutaneously injected into the backs of nude mice. Eight weeks later, subcutaneous tumors approximately 10 mm in diameter were resected, cut into 3-mm cubes, and subcutaneously implanted into 5-week-old nude mice. These tumors were removed 8 weeks after implantation when the diameter had increased to approximately 10 mm (n=35). Blood sampling was performed before resection and 1, 2, 4, 16, 56 and 100 days afterwards (n=5 each time).
Human colostral supernatant. Colostrum samples were provided by a volunteer. The supernatant was collected after centrifuging the samples at 10,000 rpm for 30 min at 4˚C. This supernatant had a high content of GAT (12) .
Antibodies. The mouse monoclonal antibodies, Mab8628 (IgG1) and Mab8513 (IgM), were provided by Konica Corp. (Tokyo). These antibodies were raised by immunizing mice against soluble human ß1,4-GalT, which was purified from the ascites of ovarian cancer patients (12) . Mab8628 could recognize both human GAT and normal human GalT, while Mab8513 only reacted with GAT and not with normal GalT (19) . Accordingly, GAT was defined as soluble human ß1,4-GalT that reacted with Mab8513, while total GalT was defined as that reacting with Mab8628, and the former was subtracted from the latter to give the normal GalT level.
Detection of total GalT and normal
GalT. In order to detect total GalT in serum samples, Western blotting was performed using Mab8628 (20) . Serum (5 µl) was mixed with 45 µl of phosphate-buffered saline (PBS: 801 mM NaHPO 4 , 1.5 mM KH 2 PO 4 , 2.7 mM KCl, 137 mM NaCl, pH 7.4) and 50 µl of sample buffer (0.125 M Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.1% bromophenol blue) to prepare a 1/20 dilution. Polyacrylamide gel (Multigel: Dai-ichi Chemicals Co., Ltd., Tokyo) with a 10 to 20% concentration gradient was used for electrophoresis. After being boiled at 96˚C for 5 min, 10 µl of the diluted sample was added to each well and electrophoresis was conducted. In addition, 50 µl of culture supernatant was mixed with 50 µl of sample buffer to prepare a 1/2 dilution, and then was treated in the same manner. After electrophoresis, protein was transferred from the gel to a membrane (Imobilon-p: Millipore, MA, USA), which was incubated with 4% Block Ace (Dainippon Pharmaceutical Co., Ltd., Osaka) for 30 min at room temperature. Mab8628 was the primary antibody used to detect total GalT, after being mixed with 4% Block Ace to adjust its concentration to 5 µg/ml. After incubation with the primary antibody at room temperature for 1 h, the membrane was washed for 10 min in 1% Block Ace with 0.01% Tween-20, and this procedure was repeated three times. Then the membrane was reacted with the secondary antibody at room temperature for 30 min. Horseradish peroxidaselabeled rabbit anti-mouse IgG1 (Zymed Laboratories, CA, USA), which was diluted to 1/1,000 with 1% Block Ace, was used as the secondary antibody. The membrane was washed in PBS three times for 10 min each and Konica Immunostain HRP-1000 (Konica Corp., Tokyo) was used for visualization. Using the standard curve obtained from human colostrum samples, the intensity of the visualized bands was quantified with NIH imaging software.
In order to detect the normal GalT fraction in the sample, the GAT fraction was adsorbed by adding Mab8513, which specifically recognizes GAT. An aliquot (50 µl) of the sample was mixed with polystyrene beads coated with Mab8513 and incubated for 2 h at 45˚C, after which the beads were exchanged and incubation was repeated. Then the beads with bound GAT were removed from the sample and Western blotting was employed to detect normal GalT. Polystyrene beads coated with bovine serum albumin (class IV, Sigma, MO, USA) were used as the control and were processed in the same manner. To confirm the adsorption of GAT to Mab8513-coated beads and its complete removal, human colostral supernatant (which has a high GAT content) was subjected to Western blotting before and after incubation with Mab8513-coated beads.
GAT assay. In order to measure GAT, a double enzymelinked immunosorbent assay was employed. Mab8513, which specifically recognizes GAT, was used as the solid-phase antibody, while Mab8628, which recognizes both GAT and normal GalT (total GalT), was used as the labeling antibody. Mab8513-coated polystyrene beads were added to a mixture of the specimen (50 µl) and PBS (200 µl), followed by incubation for 2 h at 45˚C. Then the beads were washed in PBS (1 ml) three times, mixed with horseradish peroxidaselabeled Mab8628 solution (250 µl), and incubated for 1 h at room temperature. Next, the beads were washed in PBS (1 ml) four times, and then added to 300 µl of an equal mixture of orthophenylenediamine dihydrochloride (3 mg/ml) and 0.02% H 2 O 2 to develop color for 30 min at 20˚C. The reaction was terminated by adding 1 N sulfuric acid (1 ml), and the absorbance at 492 nm was determined using a spectrophotometer. The standard curve for the assay was created using standard solutions with known concentrations of GAT.
Northern blotting. An RNeasy Mini Kit (Qiagen, Hilden, Germany) was used to extract total RNA from cultured cells. Then 10 µg of total RNA was dissolved in a mixture containing 10 µl of formamide, 3 µl of 10X MOPS buffer (0.4 M MOPS, 50 mM sodium acetate, and 20 mM EDTA), and 4 µl of formaldehyde. After heating at 65˚C for 5 min, the mixture was cooled rapidly. The cooled mixture and the loading buffer were subjected to electrophoresis on 0.1% agarose gel. Trans RNA was then transferred to a membrane (Hibond-N, Amersham, NJ, USA), which was dried at 80˚C for 2 h. The pre-hybridization solution contained 5X SSPE, 50% formaldehyde, 5X Denhalt solution, 0.5% SDS and denatured salmon sperm DNA (200 µg/ml). Pre-hybridization was done at 42˚C for 6 h, after which a [ 32 P]-ATP labeled probe was added for hybridization at 42˚C for 18 h. A DNA fragment (824 bp) was used as the probe. This fragment was cut out from the pIN-GT vector harboring the cDNA for ß1,4-GalT by using the restriction enzymes EcoRI and NotI (21) . The membrane was washed in 2X SSC/0.1% SDS for 20 min at room temperature and was subsequently washed separately in 1X SSC/0.1% SDS and 0.1X SSC/0.1% SDS for 40 min at 65˚C. Autoradiography was then performed overnight at -80˚C.
Immunohistochemistry of implanted human ovarian cancer.
The expression of human ß1,4-GalT by RMG-I tumor cells implanted in nude mice was confirmed by immunohistochemistry using Mab8628. Resected tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4-µm sections. After deparaffinization, endogenous peroxidase was blocked by 0.3% H 2 O 2 and non-specific binding was blocked with 10% normal mouse IgG (Chemicon International, Inc., CA, USA) in PBS. The primary antibody (Mab8628) was diluted to 5 µg/ml with 5% normal rabbit serum and reacted with the section for 1 h at room temperature. The secondary antibody, biotin-labeled rabbit anti-mouse IgG (H+L) (Jackson ImmunoResearch Laboratories, PA, USA), was diluted to 1/500 with 1% normal rabbit serum and reacted for 30 min at room temperature. Then the section was reacted with ABC reagent (Vector Laboratories, CA, USA) for 30 min at room temperature, followed by incubation with 0.005% diaminobenzidine (Sigma-Aldrich Japan Co., Tokyo, Japan) for 7 min to develop color. A negative control was prepared by omitting incubation with the primary antibody.
Addition of serum to human colostral supernatant. In order to investigate whether or not certain serum factors could influence the GAT concentration, human serum was added to human colostral supernatant with a high GAT content. The sample was diluted to 1/10 with PBS, and 0.1 ml of aliquots solution were tested. To examine the effect of human serum from subjects with or without ovarian cancer, serum samples collected from patients with ovarian cancer before and after tumor resection and samples collected from healthy female volunteers were added to the colostral supernatant (1:9) and the GAT level was measured after incubation at 37˚C for 4 h. Then the actual measured results were compared with the theoretical values, which were calculated using the following formula:
[(serum GAT level) x 1 + (GAT level in colostral supernatant) x 9]/10
In order to investigate whether or not serum factors could influence the total GalT concentration, serum obtained from Balb-c mice was diluted with PBS to 1/8, 1/4, and 1/2 solutions, and aliquots of these dilutions (0.1 ml) were mixed with diluted colostral supernatant and Western blotting using Mab8628 to detect total GalT was conducted. In addition to Western blotting to detect total GalT, the GAT concentration was determined in each sample (n=8).
Statistical analysis. The Mann-Whitney U test was used to compare the significance of difference between two groups for serum GAT and total GalT levels in the patients with ovarian cancer and healthy female volunteers. The paired Wilcoxon signed-ranks test was used to compare serum GAT and total GalT levels in the ovarian cancer patients before and after tumor resection. GAT levels in colostral supernatant were compared with the Mann-Whitney U test after serum from healthy volunteers or ovarian cancer patients was added. The paired Wilcoxon signed-ranks test was used to compare the decrease of GAT in the colostrum when serum obtained from ovarian cancer patients before and after tumor resection was added. A p-value of less than 0.05 was considered significant for each analysis. To assess correlations between two groups, the concentration of mouse serum added and GAT levels in colostral supernatant Pearson's correlation coefficient analysis was used. Correlations were considered significant if the p-value was <0.05 and the coefficient was >0.361.
Results

Serum total GalT, GAT, and normal GalT in ovarian cancer
patients. When compared with healthy female volunteers, the ovarian cancer patients had a significantly higher serum level of total GalT. The serum GAT level was also significantly higher in the cancer patients than in healthy women (p<0.05). Changes of serum total GalT levels varied among the cancer patients after tumor resection. However, postoperative GAT levels were decreased in all patients, indicating that there was a weak relationship between the changes of total GalT and GAT (Fig. 1) . Bands for both total GalT and normal GalT were recognized in serum samples from healthy women and ovarian cancer patients ( Fig. 2A) . As shown in Fig. 2B , the intensity ratio of the normal GalT band to the total GalT band was 0.99 in healthy women and 0.82 to 0.94 in the cancer patients, indicating that total GalT was mainly normal GalT in all these subjects. In contrast, the total GalT band in human colostral supernatant did not correspond to normal GalT, indicating that most of it was GAT. GAT was completely removed by incubation with Mab8513-coated beads (Fig. 2) .
Expression of ß1,4-GalT mRNA and GAT release by cultured cells.
Five gynecologic cancer cell lines were used to examine whether GAT release was related to the level of ß1,4-GalT mRNA expression. The relationship between the GAT concentration in the culture supernatant and the expression of ß1,4-GalT mRNA was evaluated. GAT was detected in the culture supernatant of all cell lines, but the highest concentration was produced by RMG-I, an ovarian clear cell adenocarcinoma (Fig. 3A) . Northern blotting revealed ß1,4-GalT mRNA expression by all cell lines, with the strongest expression by RMG-I (Fig. 3B) . These findings demonstrated that the GAT concentration in culture supernatant was related to the level of ß1,4-GalT mRNA expression by the tumor cells.
Normal GalT and GAT in the serum of tumor-bearing nude mice.
The human ovarian cancer cell line RMG-I, which showed the highest GAT production among the cultured cell lines, was implanted into nude mice. Subcutaneous tumors showed the typical features of clear cell adenocarcinoma, i.e., glands formed atypical cells with prominent nucleoli in clear cytoplasm. Immunohistochemistry using Mab8628 showed that the cytoplasm of the tumor cells was positive for human ß1,4-GalT (Fig. 4A) , while the control was essentially negative (Fig. 4B) .
When Mab8628 was used for Western blotting of serum samples obtained from nude mice at 8 weeks after implantation of RMG-I tumors, the existence of ß1,4-GalT in the serum was confirmed as a 47 kDa band. After GAT was adsorbed from the serum by incubation with Mab8513-coated beads, Western blotting still detected the band for normal GalT at 47 kDa, but its intensity was less than that of the total GalT band, indicating the presence of both GAT and normal GalT released into the serum by the tumor cells. Control serum from mice without implanted tumors showed no bands (Fig. 5) . GAT was undetectable in the serum from mice without tumors, while high serum levels (42±5.4 U/ml) were found in tumorbearing mice and the difference was significant (p<0.05) (Fig. 6B) . When the tumors were resected at 8 weeks after implantation, total GalT was detectable until 56 days postoperatively, but it was no longer detectable after 100 days (Fig. 6A) . On the other hand, GAT was no longer detectable from 24 h after resection (Fig. 6B) .
Effect of serum factors on GAT.
In ovarian cancer-bearing nude mice, the serum half-life of GAT released from the tumors was far shorter than that of normal GalT. To examine whether serum influenced the GAT level, human serum were added to human colostral supernatant with a high GAT content, and the measured value of GAT was consistently lower than the calculated value. With serum samples from healthy volunteers, the GAT level ranged from 52% to 63% of the calculated value. With serum from ovarian cancer patients, the GAT levels were higher (73% to 89% of the calculated value), and there was a significant difference between these two types of serum (p<0.05) (Fig. 7) . The GAT level returned to 50-65% of the calculated value when serum samples from the same patients after tumor resection were tested (Fig. 7) .
To examine whether serum factors influenced the total GalT level, various concentrations of mouse serum were added to human colostral supernatant. Western blotting for total GalT showed no definite changes in the intensity of the bands among the lanes (Fig. 8A) . In contrast, GAT was decreased in a concentration-dependent manner by addition of mouse serum and there was a significant correlation between these parameters (R=-0.843, p<0.01) (Fig. 8B) . Discussion ß1,4-GalT is a glycosyltransferase that has been known since the 1970s and elevated levels of soluble ß1,4-GalT have been reported in cancer patients since the 1980s (19, 22) . However, elevation of ß1,4-GalT also occurs in benign diseases such as hepatitis (23, 24) , meaning that the serum level of ß1,4-GalT is of little use as a tumor marker. Uemura et al investigated GAT, a fraction of soluble ß1,4-GalT, and demonstrated that elevation of the serum GAT level occurred in patients with ovarian cancer, but not in those with benign diseases (12) . Since both GAT and normal GalT (i.e., normal soluble ß1,4-GalT) are derived from the same gene product (13) , normal cells and malignant cells have the genetic potential to produce GAT as well as normal GalT. Thus, the elevation of serum GAT in ovarian cancer patients cannot be fully explained by higher levels of gene expression in tumor cells. Accordingly, we investigated another mechanism that might lead to the elevation of GAT.
We found that both total GalT and GAT levels were higher in patients with ovarian cancer than in normal women. The increase of total GalT in cancer patients was consistent with the previous finding that serum ß1,4-GalT activity is higher in cancer patients. After tumor resection, the changes of total GalT were quite variable, indicating that the serum total GalT level was influenced by factors unrelated to the malignancy. On the other hand, the serum GAT level always decreased after tumor resection and the behavior of GAT was different to that of total GalT. These findings might suggest that tumor cells selectively release GAT, while normal tissues tend to release normal GalT. Accordingly, the lack of a source of GAT following tumor resection results in a rapid decrease of the serum level, while the changes of total GalT depend on normal GalT originating from non-tumor tissues. To find evidence regarding this hypothesis, we needed to determine whether tumor cells can selectively release GAT in vivo or not.
However, it is impossible to distinguish between ß1,4-GalT produced by tumor tissue and by normal tissue in cancer patients. Therefore, we studied nude mice bearing human ovarian cancer, so that soluble ß1,4-GalT originating from the tumor cells could be selectively monitored. In nude mice implanted with RMG-I ovarian cancer cells, both GAT and normal GalT were recognized in the serum. Consequently, in patients with ovarian cancer, soluble ß1,4-GalT released by tumor cells may comprise both GAT and normal GalT. . Addition experiments using human serum. Human colostral supernatant was mixed with a 1/10 dilution of human serum. The GAT value was measured and the percent decrease relative to the calculated value was determined: [(serum GAT level) x 1 + (colostral GAT level) x 9]/10. Serum from healthy women caused a significantly larger percent reduction of GAT than preoperative serum from ovarian cancer patients (before) (p<0.05). Serum from the same patients after tumor resection (after) caused a significantly greater reduction than before resection (p<0.05) and its effect was similar to that of normal serum. After resection of the implanted tumor, normal GalT remained positive for more than 50 days in the serum of nude mice, but GAT disappeared within 24 h. This is the first demonstration that the half-life of GAT may be far shorter than that of normal GalT, which could explain the consistent decrease of serum GAT in ovarian cancer patients at 1 month after tumor resection. In other words, although tumor cells release both GAT and normal GalT, only GAT is an accurate tumor marker because of its extremely short half-life. The much shorter half-life of GAT also suggested that extracellular factors might influence the GAT concentration.
We investigated whether serum contains such factors by the addition of human serum to human colostral supernatant, which has a high GAT concentration, and we found that the measured GAT value was always lower than the calculated value. Also, a significantly greater decrease of GAT occurred when normal human serum was added than when serum from preoperative ovarian cancer patients was added, while serum obtained from these patients after tumor resection had the same effect as serum from healthy women. These findings indicated that human serum contains certain factors those decrease the GAT level. Also, the mechanism involved is inhibited in ovarian cancer patients so that a high GAT level persists.
There was no change of total GalT after the addition of mouse serum to human colostral supernatant, although a significant decrease of GAT was seen. Based on the report that the N-terminus of GAT peptide is slightly longer than that of normal GalT, the disappearance of GAT may have resulted from loss of immunoreactivity to Mab8513 (specific for GAT) due to conversion into normal GalT by serum factors, and the existence of such factors can explain the changes of serum GAT levels in human. It was also confirmed that the amount of GAT released corresponds to the level of ß1,4-GalT mRNA expression in vitro.
Based on these findings, the serum concentration of GAT may be determined by the balance between the following two mechanisms: a) the level of expression of mRNA encoding ß1,4-GalT that leads to production of GAT; and b) the extent of conversion of GAT into normal GalT.
In normal women, GAT production is suppressed and the serum level is low. Even when GAT production is stimulated in patients with certain benign diseases, the serum GAT level remains low due to conversion into normal GalT, although total GalT may be elevated. In patients with ovarian cancer, GAT production is stimulated, but inhibitory factor in the serum prevent conversion to normal GalT, resulting in the elevation GAT levels.
In this study, it was indicated that GAT is a useful tumor marker because of its extremely short half-life and it was shown that serum factors finally determine the concentration of GAT. Accordingly, determination of the factors which promote or prevent the conversion of GAT to normal GalT could contribute to clarifying the biological properties of ovarian cancer.
